In this study, we determined important performance parameters of FCM using R19M to quantify CAR19 T cells including specificity, limit of detection (LOD), lower limit of quantification (LLOQ), and precision; investigated the corresponding and consistency of ddPCR and FCM in the quantification of CAR19 T cells; and discussed the precision of ...

CD19 and CD20 are B cell–specific antigens whose expression is heterogeneous when analyzed by flow cytometry (FCM). We determined the association between CD20 expression and clinical outcome in patients with diffuse large B-cell lymphoma (DLBCL).

The simplified immunophenotyping panel, CD56/CD19/CD138(CD38)/CD45, is useful for distinguishing neoplastic myeloma cells from reactive plasma cells in clinical practice. In addition, CD19 represents the most valuable antigen for identifying …

FCM reports the proportion of CAR T cells and is quasi-quanti-tative. It takes less time to carry out an FCM assay compared with ddPCR. Moreover, high-throughput FCM allows simultaneous detec-tion of the kinetics, phenotypes, and functions of CAR T cells [14, 15].

Aug 4, 2014 · Detection of minimal residual disease (MRD) by flow cytometry (FCM) in B lymphoblastic leukemia (B ALL) is important for guiding patient-specific clinical management. We describe apparent expression of CD19 by natural killer cells as a potential confounder in the detection of B ALL MRD by FCM.

Jul 9, 2014 · Light signals were acquired with a wavelength of 488 nm for excitation and scatter measurement, an emission filter centered at 578 nm for measurement of fluorescence by R-PE conjugated CD 3, and another filter centered at 519 nm for FITC conjugated CD19.

Nov 2, 2023 · Minimal residual disease (MRD) status was determined using either multiparameter flow cytometry (FCM) or next-generation sequencing (NGS). Results: To date, 8 patients enrolled and have received CD19-CAR (n=4 at DL1; n=4 at DL2).

Feb 27, 2025 · In this issue of Blood, Koh et al 1 investigate how concurrent treatment with an anti-CD19 monoclonal antibody (mAb) can boost the antitumor efficacy of chimeric antigen receptor (CAR)–modified immune effector cells, specifically FMC63 CD19-targeted CAR natural killer and CAR T cells.

We demonstrated that flow cytometry using anti-idiotype antibody is a reliable and robust approach in the detection and quantification of CAR19 T cells in vivo and has good consistency with droplet digital PCR in monitoring CAR19 T cell kinetics.

May 15, 2020 · Flow Cytometry (FCM) The recently introduced CD19-CAR detection kit (Miltenyi Biotec™) was used to detect CAR-T-cells by FCM. In brief, anti-Biotin staining was performed with Biotin VioBright FITC antibody. Additional antibodies were used for CD3, CD4, and CD8 staining (Miltenyi Biotec™).